for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Ascendis Pharma A/S

ASND.O

Latest Trade

156.00USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

92.00

 - 

166.99

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
156.00
Open
--
Volume
--
3M AVG Volume
3.59
Today's High
--
Today's Low
--
52 Week High
166.99
52 Week Low
92.00
Shares Out (MIL)
52.84
Market Cap (MIL)
8,273.94
Forward P/E
--
Dividend (Yield %)
--

Next Event

Q3 2020 Ascendis Pharma A/S Earnings Release

Latest Developments

More

Ascendis Pharma Submits Marketing Authorisation Application For Transcon Hgh

Ascendis Pharma Says U.S. FDA Accepts Biologics License Application For Transcon HGH For Pediatric Growth Hormone Deficiency

Ascendis Pharma A/S Announces Q2 Financial Results And Business Update Conference Call On Aug. 27

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Ascendis Pharma A/S

ASCENDIS PHARMA A/S is a Danish-based biopharmaceutical company, which is involved in manufacture products for rare diseases. The Company utilizes its TransCon technologies for treatment, which can be applied to existing drug therapies, including proteins, peptides and small molecules, to create prodrugs. The Company is headquartered in Copenhagen, Denmark with offices in Heidelberg, Germany and Palo Alto, California.

Industry

Biotechnology & Drugs

Contact Info

Tuborg Boulevard 5

2900

Denmark

http://www.ascendispharma.com/

Executive Leadership

Michael Wolff Jensen

Chairman of the Board, Senior Vice President, Chief Legal Officer

Jan Moeller Mikkelsen

President, Chief Executive Officer, Board Member, Executive Director

Scott T. Smith

Chief Financial Officer, Senior Vice President

Lotte Soenderbjerg

Senior Vice President, Chief Administrative Officer

Vibeke Miller Breinholt

Senior Vice President, Nonclinical Development and Bioanalysis

Key Stats

1.55 mean rating - 11 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (EUR)

2017

-3.680

2018

-3.170

2019

-4.690

2020(E)

-6.395
Price To Earnings (TTM)
--
Price To Sales (TTM)
836.06
Price To Book (MRQ)
13.48
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
7.44
LT Debt To Equity (MRQ)
6.10
Return on Investment (TTM)
-43.49
Return on Equity (TTM)
-39.72

Latest News

Latest News

BRIEF-Ascendis Pharma Prices Public Offering Of 4.22 Mln ADSs At $142 Per Ads

* ASCENDIS PHARMA A/S ANNOUNCES PRICING OF PUBLIC OFFERING OF ADSS

BRIEF-Ascendis Pharma Announces Presentation Of Preclinical Data For Transcon Il-2 Β/Γ At AACR Virtual Annual Meeting 2020

* ASCENDIS PHARMA A/S ANNOUNCES PRESENTATION OF PRECLINICAL DATA FOR TRANSCON IL-2 Β/Γ AT AACR VIRTUAL ANNUAL MEETING 2020 Source text for Eikon: Further company coverage:

BRIEF-Ascendis Reports Q1 Loss Per Share Of EUR 1.32

* ASCENDIS PHARMA - ON TRACK FOR FILING U.S. BLA FOR TRANSCON HGH IN Q2, ADVANCING MARKETING AUTHORISATION APPLICATION IN EUROPE TO Q3

BRIEF-Ascendis Pharma Announces Top-Line Data From Fixed Dose Portion Of Phase 2 Trial Demonstrating Potential Of Transcon PTH As Replacement Therapy For Hypoparathyroidism

* ASCENDIS PHARMA A/S ANNOUNCES TOP-LINE DATA FROM FIXED DOSE PORTION OF PHASE 2 TRIAL DEMONSTRATING POTENTIAL OF TRANSCON™ PTH AS A REPLACEMENT THERAPY FOR HYPOPARATHYROIDISM

BRIEF-Ascendis Pharma Continues To Monitor And Adapt To Impact Of COVID-19

* ASCENDIS PHARMA A/S REPORTS FULL-YEAR 2019 FINANCIAL RESULTS

MOVES-Credit Suisse bolsters life sciences banking team -memo

Credit Suisse Group AG has brought on three new senior investment bankers as it continues to build out its healthcare investment banking division, according to an internal memo reviewed by Reuters.

BRIEF-Ascendis Pharma Announces Dosing Of First Subjects In Phase 1 Trial Of Transcon CNP

* ASCENDIS PHARMA A/S ANNOUNCES DOSING OF FIRST SUBJECTS IN PHASE 1 TRIAL OF TRANSCON CNP

High-profile investors bet on stocks tied to millennials: Sohn Conference

Hedge fund managers at the high-profile 2018 Sohn Investment Conference in New York pitched stock ideas on Monday that they said should benefit from the growing clout of the millennial generation, ranging from online food ordering to homebuilders.

REFILE-UPDATE 1-High-profile investors bet on stocks tied to millennials -Sohn Conference

Hedge fund managers at the high-profile 2018 Sohn Investment Conference in New York pitched stock ideas on Monday, ranging from online food ordering to homebuilders, that should benefit from the growing clout of the millennial generation.

REFILE-High-profile investors bet on stocks tied to millennials -Sohn Conference

Hedge fund managers at the high-profile 2018 Sohn Investment Conference in New York pitched stock ideas on Monday ranging from online food ordering to homebuilders that should benefit from the growing clout of the millennial generation.

BRIEF-Ascendis Pharma Reports Full Year 2017 Financial Results

* ASCENDIS PHARMA A/S REPORTS FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Ascendis Pharma prices 3.9 mln American Depositary Shares At $57 Per ADS

* ASCENDIS PHARMA A/S ANNOUNCES PRICING OF PUBLIC OFFERING OF ADSS

BRIEF-Ascendis Pharma A/S Announces Proposed Public Offering Of ADSS

* ASCENDIS PHARMA A/S ANNOUNCES PROPOSED PUBLIC OFFERING OF ADSS

BRIEF-Ascendis Pharma Says Completed Target Enrollment In Phase 3 Trial Of Pediatric Growth Hormone Deficiency Treatment

* ASCENDIS PHARMA ANNOUNCES COMPLETION OF TARGET ENROLLMENT IN PHASE 3 TRIAL OF TRANSCON GROWTH HORMONE FOR PEDIATRIC GROWTH HORMONE DEFICIENCY

BRIEF-Ascendis Pharma Initiates Submissions In Australia To Enter Study With Transcon CNP

* ASCENDIS PHARMA SAYS ON DEC 20, INITIATED REGULATORY SUBMISSIONS IN AUSTRALIA TO ENTER INTO FIRST HUMAN CLINICAL STUDY WITH TRANSCON CNP - SEC FILING Source text : (http://bit.ly/2BTTLso) Further company coverage:

BRIEF-Ascendis Pharma A/S Q3 loss per share EUR 1.04

* Ascendis Pharma A/S reports third quarter 2017 financial results

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up